This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Integrin alpha E beta 7 (ITGAE&ITGB7) Heterodimer Protein, His Tag&Tag Free
catalog :
IT7-H52W7
quantity :
1 mg, 50 ug
price :
2800 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
IT7-H52W7
product name :
Human Integrin alpha E beta 7 (ITGAE&ITGB7) Heterodimer Protein, His Tag&Tag Free
quantity :
1 mg, 50 ug
price :
2800 USD, 350 USD
quantity & price :
$350/50ug,$2800/1mg (500ug × 2)
target :
Integrin alpha E beta 7
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human ITGAE&ITGB7 Heterodimer Protein, His Tag&Tag Free (IT7-H52W7) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Ser 1124 (ITGAE) & Glu 20 - His 723 (ITGB7) (Accession # P38570-1 (ITGAE) & P26010-1 (ITGB7)).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by reduced SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human ITGAE&ITGB7 Heterodimer Protein, His Tag&Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Integrin alpha E beta 7 consist of two major subunits: Integrin alpha E (ITGAE) also known as CD103 (cluster of differentiation 103) and Integrin beta-7 is an integrin protein that in humans is encoded by the ITGB7 gene. Integrin alpha E beta 7 (CD103) is expressed mainly by cells of the T lymphocyte lineage within mucosal tissues. This is a strikingly narrow pattern of expression compared with that of other integrins. Lymphocytes expressing alpha E beta 7 are abundant in the gut and comprise a major part of the total T cell complement of the body.
The effectiveness of lung transplantation is marred by the relatively high incidence of rejection. The lung normally contains a large population of lymphocytes in contact with the airway epithelium, a proportion of which expresses the mucosal integrin, alpha(E)(CD103)beta(7). This integrin is not a homing receptor, but is thought to retain lymphocytes at the epithelial surface.
References :
(1) Smyth, L., et al., 2007, Clinical and Experimental Immunology., 149(1), 162–170.
(2) Floc’h, A. L. , et al., 2007, Journal of Experimental Medicine., 204(3), 559–570. (3) Manicone, A. M., et al., 2009, The American Journal of Pathology., 175(6), 2319–2331.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments